Skip to main content

Table 6 ADME and drug-likeness properties

From: Computer-aided molecular modeling studies of some 2, 3-dihydro-[1, 4] dioxino [2, 3-f] quinazoline derivatives as EGFRWT inhibitors

S/N

WLOGP

TPSA

GI absorption

BBB permeant

Pgp substrate

Bioavailability score

Lipinski violations

Synthetic accessibility

3

4.76

65.5

High

Yes

No

0.55

0

3.05

4

3.6

65.5

High

Yes

No

0.55

0

3.13

5

3.55

74.73

High

Yes

Yes

0.55

0

3.18

6

4.51

65.5

High

Yes

No

0.55

0

3.07

8

3.85

65.5

High

Yes

Yes

0.55

0

3.04